Same company, different methods, different outputs. Why the approaches diverge and what each one is actually for — illustrated using TechCorp, a $3B revenue software company with $600M EBITDA and a $45/share current stock price.
A common mistake in interviews is treating "valuation" as one thing. Equity research analysts and investment bankers both value companies, often using overlapping tools, but for fundamentally different purposes that produce fundamentally different outputs. An equity research analyst is asking: "What should this stock trade at in 12 months?" An investment banker is asking: "What should this company be sold for in a transaction?" Those are different questions, and the methodology follows the question. Understanding why they diverge — and by how much — is one of those conceptual distinctions that separates a well-prepared candidate from someone who has only memorized the mechanics.
Targets the public market price for investors making buy/sell/hold decisions. The analyst is measuring minority value — what a share is worth to a passive investor in a liquid market. No control premium. No synergies. The output is a 12-month price target with a rating (Buy, Hold, Sell) and a catalyst thesis for why the stock will re-rate. The audience is portfolio managers who can buy or sell today.
Targets the transaction price for a deal — fairness opinion, auction bid, pitch book. The banker is measuring control value — what the whole company is worth to an acquirer who gets to run it, realize synergies, and determine exit. Includes control premium. Includes a full methodology range (football field). The audience is a board deciding whether to sell, a buyer deciding what to bid.
Same company. Same financial statements. The outputs will look very different because the question being answered is different. An ER analyst covering TechCorp might publish a $55 price target. An IB banker advising a strategic acquirer might present a valuation range of $40–$84/share, with the top end representing full M&A value with control premium. Both are correct for their purpose.
TechCorp is a publicly traded SaaS company: $3B revenue, $600M EBITDA (20% EBITDA margin), growing at 15% annually, $200M diluted shares outstanding, $1.5B net debt. Current trading price: $45/share. An equity research analyst covering TechCorp values it as follows:
The analyst projects NTM (next twelve months) EBITDA based on their revenue model. With 15% growth, NTM EBITDA is approximately $700M. They survey a peer set of 8 comparable SaaS/enterprise software companies and determine the sector trades at 12x–15x NTM EV/EBITDA, with their best comps at 13x given TechCorp's growth rate and margin profile.
At a flat 13x multiple, the implied share price is $38 — which is below the current $45 trading price. This is where judgment comes in. The analyst believes TechCorp deserves a premium to the sector average because (1) its 15% growth is 2x the median comp at 7%, (2) its gross margins are 78% vs. 71% sector average, and (3) a new product launch creates an underappreciated growth catalyst. They apply a 15% premium to the base multiple:
The analyst believes the market is correctly pricing in a 15x multiple on current fundamentals but that the product catalyst will drive earnings upside. Incorporating a 10% earnings beat in year-2 projections and applying a 15x multiple to the higher earnings base:
After further upward revision for DCF cross-check and catalyst analysis, the analyst publishes:
RATING: BUY | 12-Month Price Target: $55 | Current Price: $45 | Upside: 22%
Thesis: TechCorp's new platform extension launching Q3 creates an underappreciated revenue stream that will accelerate NTM EBITDA to $800M+, supporting a 14x–16x multiple and $50–$60/share intrinsic range. Risk: execution on new product; management guidance conservatism creates upside optionality.
An investment banker advising TechCorp's board on a potential sale builds a full valuation range using four methodologies. The output isn't a single number — it's a football field showing the range under each approach, and the board uses it to evaluate any incoming offer against what the business is worth.
The banker uses the same 8-company peer set but applies a range rather than a point estimate: 12x–15x NTM EV/EBITDA on $700M NTM EBITDA. This produces an implied equity value range of $6,900M–$9,000M, or $34.50–$45.00/share. This is the minority, marketable value range — what the stock should trade at without a control premium.
The banker builds a 10-year projection: revenue growing 15% in years 1–3, decelerating to 10% in years 4–6, and 7% in years 7–10. EBITDA margins expand from 20% to 28% over the period as the business scales. The banker sensitizes across WACC (9%–11%) and exit multiple (12x–14x):
| WACC \ Exit Multiple | 12x | 13x | 14x |
|---|---|---|---|
| 9.0% | $52 | $57 | $62 |
| 10.0% | $46 | $50 | $55 |
| 11.0% | $41 | $44 | $48 |
DCF range: approximately $42–$58/share under base assumptions, consistent with the trading comps analysis. This is the intrinsic value range — no control premium.
The banker identifies 6 relevant M&A transactions in enterprise software over the past 4 years where the target had similar growth and margin profiles. These transactions cleared at EV/NTM EBITDA multiples of 18x–22x, reflecting the control premium and synergy value paid by strategic acquirers. Applying this range to TechCorp's $700M NTM EBITDA:
The precedents range ($55–$70/share) is materially higher than the trading comps and DCF ranges because it embeds a 35–40% control premium over the current trading price. This is what strategic buyers have historically paid in comparable transactions — it sets the floor for what TechCorp's board should demand in a sale process.
The banker also calculates what a PE firm could pay and still achieve a 20% IRR — this is the financial buyer floor. If a financial sponsor can't make the return math work, any offer below the floor is a bad deal for shareholders. The LBO analysis (see below) implies a financial buyer maximum entry price of approximately $32–$36/share. This tells the board: any offer below $32/share is below even a financial buyer's floor, meaning either the deal terms are wrong or the management plan is too conservative.
| Dimension | Equity Research | Investment Banking |
|---|---|---|
| Purpose | 12-month price target for investors | Transaction valuation for boards/buyers |
| Primary metric | P/E, NTM EV/EBITDA | Multi-method football field |
| Control premium | Not included | Included in precedent transactions |
| Audience | Portfolio managers, public investors | Boards, management, acquirers |
| Synergies | Standalone only | Buyer synergies in strategic analysis |
| Bias disclosure | Explicit (Buy/Hold/Sell rating) | Fairness opinion standard |
| Model depth | Revenue / EPS focused | Full 3-statement + synergy model |
| DCF role | Cross-check / secondary | Primary methodology (alongside comps) |
| LBO analysis | Rarely used | Financial buyer floor, always in IB book |
| Precedent transactions | Occasionally referenced | Core methodology, sets control premium floor |
An equity research analyst is valuing what a public market investor pays for a minority stake — a few thousand shares with no ability to influence strategy, capital allocation, or exit timing. An investment banker is valuing what an acquirer pays to own and operate the entire business. The acquirer gets the control premium: the right to run the business as they see fit, eliminate redundant costs, integrate distribution, and eventually sell or IPO at the time of their choosing. That option has real economic value, and it's consistently worth 25–40% above the unaffected stock price. For TechCorp: the ER analyst publishes a $55 price target based on minority-stake public market valuation. If TechCorp gets acquired tomorrow, the expected transaction price based on precedents is $55–$70/share — the ER target sits at the low end of the M&A range. The ER analyst was not wrong; they were right about minority value. The $10–$15/share premium above that is the control premium — economically distinct from the minority price.
The LBO analysis is unique to the investment banking context. A PE buyer needs to generate a 20%+ IRR over a 5-year hold period. Working backward from that return target constrains the maximum entry price. For TechCorp:
| Item | Amount | Notes |
|---|---|---|
| LTM EBITDA | $600M | Entry EBITDA |
| Max Leverage (5.5x) | $3,300M | Debt capacity at 5.5x EBITDA |
| Year 5 EBITDA (15% CAGR) | $1,207M | Growth through hold period |
| Exit EV (13x Year 5 EBITDA) | $15,690M | Exit multiple = entry sector multiple |
| Less: Exit Net Debt | ($1,800M) | Debt paydown from FCF over 5 years |
| Exit Equity Value | $13,890M | |
| Required Entry Equity (20% IRR) | $5,585M | Exit equity ÷ (1.20)^5 = $13,890M ÷ 2.49 |
| Plus: Entry Debt | $3,300M | |
| Max Supportable Entry EV | $8,885M | |
| Less: Existing Net Debt | ($1,500M) | |
| Max Equity Value (PE Buyer) | $7,385M | |
| LBO Floor per Share | $36.93 | $7,385M ÷ 200M diluted shares |
The LBO floor is approximately $37/share. This tells TechCorp's board: no transaction below $37/share is attractive — even a PE buyer with pure financial buyer economics could justify paying $37. The strategic buyer floor is higher ($55+) because synergies increase the EBITDA being valued. If any acquirer comes in below $37/share, walk away — you're below the floor of what even a leveraged financial buyer with a 20% return hurdle would pay.
This is why the LBO analysis is always in an IB pitch book. It's not just relevant when PE is the buyer — it anchors the minimum value that any transaction must exceed. A board that accepts $35/share in a strategic deal when the LBO floor is $37/share has left value on the table by a quantifiable amount.
The ER analyst values minority interest in a public market — no control premium, no synergies, liquid minority stake. An acquirer pays for control, which includes the right to run the business, realize synergies, and extract value over a multi-year horizon. The control premium — historically 25–40% of unaffected stock price — closes the gap between ER target and M&A price. For TechCorp at $45/share: ER target $55, M&A precedents suggest $55–$70/share. The ER analyst was right for a public investor; the M&A banker is right for an acquirer. Different questions, different answers.
The LBO floor is the maximum price a financial sponsor can pay and still achieve their return hurdle — typically 20% IRR over a 5-year hold — given available leverage and projected exit value. It matters in M&A because it sets a hard minimum: any deal price below the LBO floor means the company is being sold for less than a purely financial buyer would have paid with debt financing. Strategic acquirers almost always pay above the LBO floor because synergies increase their effective EBITDA being valued. If a strategic offer comes in below the LBO floor, the board has three options: renegotiate, run a process to find a better buyer, or reject the offer and remain independent.
Trading comps are anchored to current market sentiment, which can be distorted — sectors get overvalued in bull markets and undervalued in downturns. The DCF provides an intrinsic value anchor that's independent of what the market is doing today. In a pitch or fairness opinion, showing that the DCF supports the transaction price range gives the board comfort that the valuation is grounded in fundamentals, not just market multiples that could look very different in a different macro environment. The DCF is also the right tool for capturing specific value drivers that aren't reflected in a peer multiple — a particular cost improvement program, a new product cycle, or a synergy assumption that only applies to this specific transaction. Comps tell you what the market pays; DCF tells you what the business is worth intrinsically. You need both.
Several reasons: (1) the analyst may be wrong — their assumptions for revenue growth or margin expansion may be too optimistic, and the market is pricing a more conservative scenario; (2) the catalyst hasn't materialized yet — the stock will re-rate when the event (product launch, earnings beat, contract announcement) actually happens; (3) the market is applying a higher risk discount — investors may agree with the analyst's projections but are discounting at a higher rate due to execution risk or sector headwinds; (4) there's a buyer/seller imbalance — institutions may be reducing tech exposure for portfolio construction reasons unrelated to TechCorp's fundamentals. An ER analyst's price target is not an arbitrage opportunity — it's a forecast that depends on both the fundamental thesis being correct and the catalyst actually arriving within the 12-month window.